SOURCE: CEGEDIM

December 15, 2010 13:10 ET

Cegedim Strategic Data Expands China Promotion Audit in 2011

Rep Levels Compare to Major Western Markets

PARIS--(Marketwire - December 15, 2010) - Cegedim Strategic Data (CSD), leading provider of integrated healthcare research, expands China Promotion audit in 2011.

From January 2011, CSD will increase its audit of pharmaceutical sales force and marketing channel promotion from 10 to 13 cities, and will also increase the number of specialist panels from 17 to 19 adding Infectious Diseases and Rheumatologists. Third quarter 2010 results from the current audit of 17 different hospital specialist panels reveal that China now ranks 4th in volume of rep calls among 39 audited countries and 3rd in total full time rep equivalents (FTE), behind the US and Japan.

"We're now seeing comparable sales force levels that place China in the top tier worldwide along with the major 5 Europe, US and Japan in terms of volume. Roughly 13% of total pharmaceuticals sales reps worldwide are now working in China and CSD is the only agency in a position to monitor the dynamics of this leading emerging market. We have been auditing SFE and delivering promotion analytics on China since 2004 so we can bring a wealth of experience and insight to the industry", commented Christopher Wooden, Vice President for Promotional audits at CSD.

Industry sales force size and rep call volumes are up 13% over the same period in 2009 and this is in line with expectations given double digit sales growth and the importance the industry is placing on a market it considers the key to future profits.

Among leading promoted drug classes, anti-infectives, hypertension and diabetes represent over 25% of total promotional spending in China. CSD audits and projects promotional spending on sales force, meetings & events, samples, clinical trials, advertising and mailing. In the 12 months to September 2010, there have been heavy sales and marketing investments in the above mentioned drug classes.

"The most successful companies in China will be those that adapt the sales and marketing expertise built up in the west over many years to this market. Getting the fundamentals right now is crucial. Companies that invest too little will fall behind but there is a real potential for overinvestment as well. Data driven decisions will be a key to finding the right balance" observes Delphine Perridy, Managing Director of CSD China.

About Cegedim Strategic Data:
CSD is a leading Market Research company dedicated to the healthcare industry and operating worldwide. With over 36 years experience in the Pharmaceutical industry, CSD offers a comprehensive range of market research services and solutions to its customers, which include more than 50 global and 500 local Pharmaceutical companies. CSD integrates primary and secondary analyses with its medical expertise to meet its customer's research needs.
To learn more, please visit our website: www.cegedimstrategicdata.com

About Cegedim:
Founded in 1969, Cegedim is a global technology and services company specializing in the healthcare field. Cegedim supplies services, technological tools, specialized software, data flow management services and databases. Its offerings are targeted notably at healthcare industries, life sciences companies, healthcare professionals and insurance companies. The world leader in life sciences CRM, Cegedim is also one of the leading suppliers of strategic healthcare industry data. Cegedim employs 8,600 people in more than 80 countries and generated revenue of EUR 874 million in 2009. Cegedim SA is listed in Paris (EURONEXT: CGM).
To learn more, please visit: www.cegedim.com

CSD expands China promotion audit in 2011
http://hugin.info/141732/R/1472982/409399.pdf

Contact Information